VERTEX PHARMACEUTICALS INC / MA — Director's Dealing 2012

May 16, 2012

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: VERTEX PHARMACEUTICALS INC / MA (VRTX)
CIK: 0000875320
Period of Report: 2012-05-14

Reporting Person: Wysenski Nancy (EVP, Chief Commercial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2012-05-14	Common Stock	M	4531	$37.86	Acquired	36763	Direct
2012-05-14	Common Stock	M	147071	$39.70	Acquired	183834	Direct
2012-05-14	Common Stock	M	25000	$39.70	Acquired	208832	Direct
2012-05-14	Common Stock	M	3398	$38.80	Acquired	212232	Direct
2012-05-14	Common Stock	S	179628	$64.27	Disposed	32604	Direct
2012-05-14	Common Stock	S	372	$65.00	Disposed	32232	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2012-05-14	Stock Option	$37.86	M	4531	Disposed	2022-02-01	Common Stock (4531)	Direct
2012-05-14	Stock Option	$39.70	M	147071	Disposed	2019-12-08	Common Stock (147071)	Direct
2012-05-14	Stock Option	$39.70	M	25000	Disposed	2019-12-08	Common Stock (25000)	Direct
2012-05-14	Stock Option	$38.80	M	3398	Disposed	2021-02-02	Common Stock (3398)	Direct

Footnotes

F1: Transaction made pursuant to Ms. Wysenski's company approved trading plan under Rule 10b5-1.

F2: Open market sales reported on this line occurred at a weighted average price of $64.27 (range $63.90 to $64.82).

F3: Ms. Wysenski undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.